Keyword: PRA Health Sciences
PRA has established a new Rare Disease Advisory Committee designed to help integrate the needs of patients into rare disease studies.
Symphony Health has inked a new deal with Close-Up International aimed at boosting its global data services.
Nearly three years after it first teamed up with Takeda, PRA Health Sciences has bought out its joint venture with the Japanese pharma.
PRA will buy health data and analytics expert Symphony Health for $530 million up front as it reports 16% second-quarter service revenue growth.
Takeda inked a multiyear, $170 million-per-program drug discovery partnership with Schrödinger.
Ex-Novo exec Høiland became Radius' CEO, ex-Sanofi Genzyme CEO Meeker joined Trevi as chairman, Myovant tapped four execs with Big Pharma experience.
DelMar is advancing its first-in-class brain cancer med dianhydrogalactitol (VAL-083) into phase 3, and it has recruited PRA Health Sciences to conduct that pivotal study.
U.K.-based CRO Chiltern has put itself up for sale as it continues the bullish M&A run for contract research groups that has seen a host of deals, JVs and mergers over the last 2 years.
Takeda is nearing the final stages of a joint venture with PRA Health Sciences, the product of an expansion of their clinical development partnership in Japan announced in February.
A bipartisan bill that plans to allow a tax credit for expenses of contracted research—often done by CROs—has been introduced in the House of Representatives.